China Senile Dementia Drug Market Report

The Chinese Dementia Drug Utilization

Publication Date	March 2009
Publisher	Draco Healthcare Cons.
Product Type	Report
Pages	140
ISBN Number	not applicable
Product Code	DHC00010

Buy this product or for assistance call +44 20 7060 7474

PDF £4,810.00$8001 | €5384

PRINT £5,110.00$8500 | €5719

CD-ROM £4,810.00$8001 | €5384

FAX Order above formats by FAX

Summary

By conservative estimates, there are about 6 million Chinese senile dementia (SD) patients (including vascular dementia, Alzheimer's disease and other types of dementia patients). It is estimated that there will be 250 million senior Chinese of 60 years or older by the year 2025, and among which there will be 10.09 million senile dementia patients.

Sales of senile dementia drugs in the Chinese hospital market have risen steadily since 2003. The annual growth rates in 2003, 2004, 2005, 2006 and 2007 are 4.72%, 25.49%, 11.06%, 10.87% and 20.65% respectively. The annual sales of dementia drugs in 2007 are about RMB 6.042 billions (close to USD 1 billion), almost doubled that in 2003 (RMB 3.24 billion in 2003).

This report has systemically analyzed the Chinese dementia drug market. All drug data are based on hospital drug prescription and drug purchasing data from the hospital data monitor system that the China Nan Fang Institute of Medical and Economic Information has developed and maintained (Nan Fang Institute is a direct subsidiary of the Chinese State Food and Drug Administration, the SFDA). Sampled hospitals are from major Chinese cities across different geographic locations, including Beijing, Shanghai, Guangzhou, Nanjing, Chengdu, Chongqing, Xian, Shenyang, Harbin and Zhengzhou, covering significant percentages of all hospitals in these regions.

Market shares from all major players including multinational and Chinese pharmaceutical companies and their major dementia products are analyzed systemically based on data from significant number of Chinese hospitals. The comprehensive hospital utilization data of major dementia drugs will present you a clear picture of the competition landscape of Chinese dementia drug market and the market potential for your company's product(s) that already marketed in China or if you are planning to bring your drugs to the China market.

This China Dementia Drug Market Report has been a Must-have reference for all levels of decision makers in pharmaceutical companies, medical device companies, healthcare investing companies and healthcare consulting companies. These unique drug prescription and utilization data can provide valuable information for new product development, marketing and strategic planning functions for pharmaceutical companies. Compared to expensive customized drug reports in China, this multi-client report provides significant savings and great cost/benefit to pharmaceutical companies and interested parties.

Content

Chapter I: Overview of Dementia Drugs 8 Section 1: Drug Development for Senile Dementia
- 1. Pathogenesis of Senile Dementia
  - 1.1. Theory of the Abnormal Microtubule Associated Protein (Tau)
  - 1.2 A Toxicity Theories
  - 1.3 Gene Mutation Theory 9 Section 2: Classification of Senile Dementia Drugs
- 1. Cholinergic Receptor Agonist (CRA)
  - 1.1 M Type of Cholinergic Receptor Agonist
  - 1.2 Nicotinic Receptor Agonist
- 2. Cholinesterase Inhibitor
  - 2.1 Donepezil
  - 2.2 Rivastigmine
  - 2.3 Galantamin
  - 2.4 Huperzine A
  - 2.5 Ganstigmine
  - 2.6 Physostiamine
  - 2.7 Phenserine and Tolserine
- 3. Drugs Acting on NMDA Receptor
- 4. Amyloid -protein (A) Forming Inhibitor
- 4.1Cholesterol Reducing Drugs
  - 4.2 Nonsteroidal Anti-inflammatory Drugs (NSAID)
  - 4.3 Estrogen
  - 4.4 Metal Chelator
- 5. Antioxidant
- 6. Calcium Antagonist
- 7. Nerve Growth Factor (NGF) and Nerve Stem Cells (NSCs)
- 8. A Vaccine
- 9. Gene Therapy
- 10. Prospects
Chapter II: Global Dementia Drug Market
Chapter III: The Chinese Dementia Drug Market
- Section 1: The Chinese Market of Senile Dementia Drugs
- Section 2: Market Shares of Top Dementia Drugs
- Section 3: Market Shares of Top Manufacturers
- Section 4: Growth Rates of Top Senile Dementia Drugs
- Section 5: Market Potential of Brand Dementia Drugs
- Section 6: Top 10 Brand Dementia Drugs in China 2006-2007
- 1. Market Shares and Sizes of Ginkgo Biloba Extract by Manufacturers 2005-2007
- 2. Market Shares and Sizes of Ganglioside by Manufacturers 2005-2007
- 3. Market Shares and Sizes of Oxiracetam by Manufacturers 2005-2007
- 4. Market Shares and Sizes of Breviscapine by Manufacturers 2005-2007
- 5. Market Shares and Sizes of Edaravone by Manufacturers 2005-2007
- 6. Market Shares and Sizes of Vinpocetine by Manufacturers 2005-2007
- 7. Market Shares and Sizes of Meclofenoxate (Luzhixing) by Manufacturers 2005-2007
- 8. Market Shares and Sizes of Nicergoline by Manufacturers 2005-2007
- 9. Market Shares and Sizes of Rat Nerve Growth Factor (rNGF) by Manufacturers 2005-2007
- 10. Market Shares and Sizes of Almitrine/raubasine by Manufacturers 2005-2007
Chapter IV: Brand Names, Generic Names, Formulas and Manufacturers of Dementia Drugs in China
- Section 1: Brand Names, Generic Names, Formulas and Manufacturers of Allergy Drugs in China
- Section 2: Brand Names, Generic Names, Formulas, Manufacturers and Approval Time of Newly Approved Dementia Drugs
Chapter V: Dementia Drugs on the National Basic Healthcare Insurance List
- Section 1: Names, Formulas, Packages and Retail Prices (by Regions) of Dementia Drugs
- Section 2: Dementia Drugs (Chemical Drugs) on the National Basic Healthcare Insurance List
- Section 3: Dementia Drugs (TCMs) on the National Basic Healthcare Insurance List
Chapter VI: Overview of R&D for Dementia Drugs
- Section 1: Amyloid- Protein as Immunotherapy for Alzheimer's Disease
- 1. Immunotherapy with Amyloid- Protein
  - 1.1 Passive Immunotherapy
  - 1.2 Active Immunotherapy
  - 1.3 Gene Immunotherapy
  - 1.4 Clinic trials for A immunotherapy
- 2. Mechanism of A Immunotherapy
- 3. Adverse Reactions from A Immunotherapy
- 4. Prospects
- Section 2: R&D of Traditional Chinese Medicines for the Treatment of Alzheimer's Disease
- 1. Ginkgo biloba L and Ginkgo Active Ingredients
- 2. Huperzia serrata Thunb and Huperzine Compounds
- 3. Salvia miltiorrhiza Bung and Salvia miltiorrhiza Active Ingredients
- 4. Panax ginseng C.A.Mayer and Panaxoside
- 5. Other Chinese Herb Monomers and Active Ingredients
- 6. Compound TCM
Exhibits
- Table 1: Marketed Drugs for the Treatment of Alzheimer's Disease
- Table 2: Drugs for Alzheimer's Disease in Phase III Studies
- Table 3: Market Shares of Top 20 Dementia Drugs in China 2005-2007
- Table 4: Market Sizes of Top 20 Dementia Drugs in China 2005-2007
- Table 5: Market Shares of Top 20 Pharmaceutical Companies in the Chinese Dementia Drug Market 2005-2007
- Table 6: Market Sizes of Top 20 Pharmaceutical Companies in the Chinese Dementia Drug Market 2005-2007
- Table 7:Annual and Compound Annual Growth Rates of Top 20 Dementia Drugs in the Chinese Market 2005-2007
- Table 8: Market Shares of Ginkgo Biloba Extract by Manufacturers 2005-2007
- Table 9: Market Sizes of Ginkgo Biloba Extract by Manufacturers 2005-2007
- Table 10: Market Shares of Ganglioside by Manufacturers 2005-2007
- Table 11: Market Sizes of Ganglioside by Manufacturers 2005-2007
- Table 12: Market Shares of Oxiracetam by Manufacturers 2005-2007
- Table 13: Market Sizes of Oxiracetam by Manufacturers 2005-2007
- Table 14: Market Shares of Herba Erigerontis by Manufacturers 2005-2007
- Table 15: Market Sizes of Herba Erigerontis by Manufacturers 2005-2007
- Table 16: Market Shares of Vinpocetine by Manufacturers 2005-2007
- Table 17: Market Sizes of Vinpocetine by Manufacturers 2005-2007
- Table 18: Market Shares of Meclofenoxate by Manufacturers 2005-2007
- Table 19: Market Sizes of Meclofenoxate by Manufacturers 2005-2007
- Table 20: Market Shares of Nicergoline by Manufacturers 2005-2007
- Table 21: Market Sizes of Nicergoline by Manufacturers 2005-2007
- Table 22: Market Shares of rNGF by Manufacturers 2005-2007
- Table 23: Market Sizes of rNGF by Manufacturers 2005-2007
- Table 24: Brand Names, Generic Names, Formulas and Manufacturers of Allergy Drugs in China
- Table 25: Brand Names, Generic Names, Formulas and Manufacturers of Dementia Drugs in China
- Table 26: Names, Formulas, Packages and Retail Prices of Dementia Drugs in China
- Table 27: Chemical Dementia Drugs on the National Basic Healthcare Insurance List
- Table 28: TCM Dementia Drugs on the National Basic Healthcare Insurance List
- Figure 1: Sales and Market Growth of Chinese Dementia Drugs 2003-2007
- Figure 2: Future Potential of Top Anti-senile Dementia Drugs in China
- Figure 3: Top 10 Branded Dementia Drugs in 2006
- Figure 4: Top 10 Branded Dementia Drugs in 2007
Top 20 Pharmaceutical Companies in the Chinese Dementia Drug Market (with at least 1.86% of the total dementia drug market in 2007)
- Harbin Sanlian
- Beijing Shuanghe
- Guangdong Shixin
- Guizhou Yibai
- Hainan Tongyong Sanyang
- Heilongjiang Feixia
- Heilongjiang Zhenbaodao
- Henan Lingrui
- Kunming Longjin
- Nanjing Xiansheng Dongyuan
- Shandong Qilu
- Shanghai Xinxianfeng
- Shanxi Pude
- Shanxi Wanrong
- Shijiazhuang Shenwei
- TRB Pharma S.A.
- Willmar Schwabe
- Yangtze River
- Yunnan Shengwugu Dengzhanhua (Herba Erigerontis)
- Hunan Jianlang